/SERA
SERA Stock - Sera Prognostics, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$3.60+0.14%
+$0.01 (+0.14%) • Jan 13
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.80
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+38.9%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SERA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.56 – $3.64
TARGET (TP)$5.00
STOP LOSS$3.31
RISK/REWARD1:4.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.99
52W High$6.92
52W Low$1.37
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $77,000 | $306,000 | $268,000 | $82,000 | $25,000 |
| Gross Profit | $-5,000 | $96,000 | $75,000 | $45,000 | $14,000 |
| Gross Margin | -6.5% | 31.4% | 28.0% | 54.9% | 56.0% |
| Operating Income | $-36,635,000 | $-39,821,000 | $-45,652,000 | $-35,395,000 | $-17,971,000 |
| Net Income | $-32,898,000 | $-36,242,000 | $-44,186,000 | $-35,009,000 | $-19,848,000 |
| Net Margin | -42724.7% | -11843.8% | -16487.3% | -42693.9% | -79392.0% |
| EPS | $-0.99 | $-1.16 | $-1.43 | $-1.18 | $-1.19 |
Company Overview
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 38.9% Upside
Now
$5
Low
$5
Average
$5
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Jefferies | Initiation | Buy | $5 |
Earnings History & Surprises
SERABeat Rate
44%
Last 18 quarters
Avg Surprise
-10.8%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.25vs$-0.25
Q2 24
-8.7%
$-0.25vs$-0.23
Q3 24
-8.7%
$-0.25vs$-0.23
Q4 24
-9.1%
$-0.24vs$-0.22
Q1 25
-8.7%
$-0.25vs$-0.23
Q2 25
+16.7%
$-0.20vs$-0.24
Q3 25
+23.8%
$-0.16vs$-0.21
Q4 25
+15.8%
$-0.16vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 18, 2026 | $-0.17 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.21 | $-0.16 | +23.8% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.24 | $-0.20 | +16.7% | ✓ BEAT |
Q1 2025 | Mar 19, 2025 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.25 | $-0.25 | 0.0% | = MET |
Q4 2023 | Nov 8, 2023 | $-0.30 | $-0.23 | +23.3% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.34 | $-0.34 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-0.35 | $-0.34 | +2.9% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.42 | $-0.31 | +26.2% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.40 | $-0.35 | +12.5% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.40 | $-0.37 | +7.5% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.34 | $-0.40 | -17.6% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.29 | $-0.41 | -41.4% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.22 | $-0.39 | -77.3% | ✗ MISS |
Q3 2021 | Aug 30, 2021 | $-1.26 | $-3.17 | -151.6% | ✗ MISS |
Q3 2021 | Jul 16, 2021 | — | $-0.21 | — | — |
Latest News
Sera Prognostics shares are trading higher after a randomized controlled trial validated the PreTRM Test's effectiveness in identifying women at higher risk of spontaneous preterm birth and guiding preventive care.
📈 PositiveBenzinga•Jan 7, 2026, 06:11 PM
Sera Prognostics Announces Randomized Trial Finds PreTRM Test Improves Outcomes By Identifying Women At Risk For Preterm Birth
📈 PositiveBenzinga•Jan 7, 2026, 01:40 PM
Sera Prognostics Announces Findings Of Prematurity Risk Assessment Combined With Clinical Interventions For Improved Neonatal OutcoMEs Study Accepted For Publication In Peer-Reviewed Journal
📈 PositiveBenzinga•Nov 24, 2025, 01:10 PM
Sera Prognostics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $16.000K Miss $85.000K Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:09 PM
Frequently Asked Questions about SERA
What is SERA's current stock price?
Sera Prognostics, Inc. (SERA) is currently trading at $3.60 per share. The stock has moved +0.14% today.
What is the analyst price target for SERA?
The average analyst price target for SERA is $5.00, based on 1 analyst.
What sector is Sera Prognostics, Inc. in?
Sera Prognostics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is SERA's market cap?
Sera Prognostics, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does SERA pay dividends?
No, Sera Prognostics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPYX
Apyx Medical Corporation
$3.88
Mkt Cap: $0.1B
ATOS
Atossa Therapeutics, Inc.
$0.64
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.43
Mkt Cap: $0.1B
HURA
TuHURA Biosciences, Inc.
$0.73
Mkt Cap: $0.0B
LUCD
Lucid Diagnostics Inc.
$1.19
Mkt Cap: $0.1B
ONCY
Oncolytics Biotech Inc.
$1.00
Mkt Cap: $0.1B
RPID
Rapid Micro Biosystems, Inc.
$3.11
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$20.65
Mkt Cap: $0.2B
STSS
Sharps Technology, Inc.
$2.08
Mkt Cap: $0.1B
TVGN
Tevogen Bio Holdings Inc.
$0.31
Mkt Cap: $0.1B
Explore stocks similar to SERA for comparison